5.12
+0.09
(1.79%)
Jun 18 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.00 - 5.14 |
| 52 week | 4.26 - 7.55 |
| Open | 5.03 |
| Vol / Avg. | 93,921.00/220,685.00 |
| Mkt cap | 155.48M |
| P/E | - |
| Div/yield | - |
| EPS | -0.75 |
| Shares | 30.37M |
| Beta | 1.38 |
| Inst. own | 57% |
Events
Jul 29, 2013
Q2 2013 POZEN Inc. Earnings Release
Jun 6, 2013
POZEN Inc. Annual Shareholder Meeting
Jun 3, 2013
POZEN Inc. at Jefferies Global Healthcare Conference -
May 8, 2013
Q1 2013 POZEN Inc. Earnings Conference Call -
May 1, 2013
Q1 2013 POZEN Inc. Earnings Release
Apr 18, 2013
POZEN Inc. Management to Discuss the PA Program - Conference Call -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -408.33% | -472.67% |
| Operating margin | -410.10% | -477.50% |
| EBITD margin | - | -476.66% |
| Return on average assets | -27.01% | -23.95% |
| Return on average equity | -28.41% | -26.67% |
| Employees | 29 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 400, 1414 Raleigh Rd
CHAPEL HILL, NC 27517
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)
CHAPEL HILL, NC 27517
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
POZEN Inc. (POZEN), is a pharmaceutical company focused on transforming medicine. The Company had developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. On November 23, 2011, the Company entered into a Purchase and Sale Agreement with CPPIB Credit Investments Inc (CII,), pursuant to which it sold, and CII purchased, its right to receive future royalty payments arising from United States sales of MT 400, including Treximet.
Officers and directors
| John R. Plachetka Pharm.D. | Chairman of the Board, President, Chief Executive Officer | |
| William L. Hodges CPA | Chief Financial Officer, Senior Vice President - Finance and Administration | |
| Elizabeth A. Cermak | Executive Vice President, Chief Commercial Officer | |
| Gilda M. Thomas J.D. | Senior Vice President, General Counsel | |
| John E. Barnhardt CPA | Vice President - Finance and Administration | |
| John G. Fort M.D. | Chief Medical Officer | |
| Kenneth B Lee Jr. | Lead Independent Director | |
| Neal F Fowler | Independent Director | |
| Arthur S. Kirsch | Independent Director | |
| Martin Nicklasson | Independent Director |